Methadone vs. morphine SR for treatment of neuropathic pain: A randomized controlled trial and the challenges in recruitment
Introduction: Accumulating evidence has identified a number of advantages for methadone over other opioids for the treatment of chronic pain including: agonist action at both μ and δ opioid receptors, N-methyl-d-aspartate (NMDA) antagonist activity and the ability to inhibit the reuptake of monoamin...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2019-01-01
|
Series: | Canadian Journal of Pain |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/24740527.2019.1660575 |
id |
doaj-2f8c962341f3427a89317daf1084483f |
---|---|
record_format |
Article |
spelling |
doaj-2f8c962341f3427a89317daf1084483f2021-01-04T18:52:24ZengTaylor & Francis GroupCanadian Journal of Pain2474-05272019-01-013118018910.1080/24740527.2019.16605751660575Methadone vs. morphine SR for treatment of neuropathic pain: A randomized controlled trial and the challenges in recruitmentMary Lynch0Dwight Moulin1Jordy Perez2Dalhousie UniversityWestern UniversityAlan Edwards Pain Management UnitIntroduction: Accumulating evidence has identified a number of advantages for methadone over other opioids for the treatment of chronic pain including: agonist action at both μ and δ opioid receptors, N-methyl-d-aspartate (NMDA) antagonist activity and the ability to inhibit the reuptake of monoamines. It was hypothesized that with these three mechanisms of action methadone might be a good option for the treatment of neuropathic pain. Methods: This was a double-blind randomized controlled trial comparing methadone to controlled-release morphine. The primary objective was to determine whether methadone is clinically inferior versus noninferior to morphine as an analgesic. Results: We attempted recruitment at three academic pain centers over a 3-year period. In the end only 14 participants were able to be recruited; 5 withdrew and only 9 completed the trial. This study was underpowered. All participants showed a mean reduction in pain intensity according to the Numeric Rating Scale for Pain Intensity (morphine 5.86 to 4.38, methadone 6.11 to 4.5) and reported pain relief compared to pretreatment, but the sample size was too small for statistical analysis. Discussion: Reasons for challenges in recruitment included tight inclusion and exclusion criteria and high participant burden. In addition, there was significant heterogeneity of patients between the three sites, leading to differences in reasons for exclusion. This included seemingly disparate reasons at the different sites, including few participants who were methadone naïve vs. avoidance or fear of opioids. In the end, we were unable to answer the question of the study.http://dx.doi.org/10.1080/24740527.2019.1660575neuropathic painopioidsmethadonestudy recruitment |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Mary Lynch Dwight Moulin Jordy Perez |
spellingShingle |
Mary Lynch Dwight Moulin Jordy Perez Methadone vs. morphine SR for treatment of neuropathic pain: A randomized controlled trial and the challenges in recruitment Canadian Journal of Pain neuropathic pain opioids methadone study recruitment |
author_facet |
Mary Lynch Dwight Moulin Jordy Perez |
author_sort |
Mary Lynch |
title |
Methadone vs. morphine SR for treatment of neuropathic pain: A randomized controlled trial and the challenges in recruitment |
title_short |
Methadone vs. morphine SR for treatment of neuropathic pain: A randomized controlled trial and the challenges in recruitment |
title_full |
Methadone vs. morphine SR for treatment of neuropathic pain: A randomized controlled trial and the challenges in recruitment |
title_fullStr |
Methadone vs. morphine SR for treatment of neuropathic pain: A randomized controlled trial and the challenges in recruitment |
title_full_unstemmed |
Methadone vs. morphine SR for treatment of neuropathic pain: A randomized controlled trial and the challenges in recruitment |
title_sort |
methadone vs. morphine sr for treatment of neuropathic pain: a randomized controlled trial and the challenges in recruitment |
publisher |
Taylor & Francis Group |
series |
Canadian Journal of Pain |
issn |
2474-0527 |
publishDate |
2019-01-01 |
description |
Introduction: Accumulating evidence has identified a number of advantages for methadone over other opioids for the treatment of chronic pain including: agonist action at both μ and δ opioid receptors, N-methyl-d-aspartate (NMDA) antagonist activity and the ability to inhibit the reuptake of monoamines. It was hypothesized that with these three mechanisms of action methadone might be a good option for the treatment of neuropathic pain. Methods: This was a double-blind randomized controlled trial comparing methadone to controlled-release morphine. The primary objective was to determine whether methadone is clinically inferior versus noninferior to morphine as an analgesic. Results: We attempted recruitment at three academic pain centers over a 3-year period. In the end only 14 participants were able to be recruited; 5 withdrew and only 9 completed the trial. This study was underpowered. All participants showed a mean reduction in pain intensity according to the Numeric Rating Scale for Pain Intensity (morphine 5.86 to 4.38, methadone 6.11 to 4.5) and reported pain relief compared to pretreatment, but the sample size was too small for statistical analysis. Discussion: Reasons for challenges in recruitment included tight inclusion and exclusion criteria and high participant burden. In addition, there was significant heterogeneity of patients between the three sites, leading to differences in reasons for exclusion. This included seemingly disparate reasons at the different sites, including few participants who were methadone naïve vs. avoidance or fear of opioids. In the end, we were unable to answer the question of the study. |
topic |
neuropathic pain opioids methadone study recruitment |
url |
http://dx.doi.org/10.1080/24740527.2019.1660575 |
work_keys_str_mv |
AT marylynch methadonevsmorphinesrfortreatmentofneuropathicpainarandomizedcontrolledtrialandthechallengesinrecruitment AT dwightmoulin methadonevsmorphinesrfortreatmentofneuropathicpainarandomizedcontrolledtrialandthechallengesinrecruitment AT jordyperez methadonevsmorphinesrfortreatmentofneuropathicpainarandomizedcontrolledtrialandthechallengesinrecruitment |
_version_ |
1724348967694630912 |